Abstract
Background
Functional hypothalamic amenorrhea (FHA) is a form of chronic anovulation not due to identifiable organic causes and with adverse health consequences. The identification of women with this disorder or the precocious identification of women at risk is based on the knowledge of lifestyle risk factors or behaviors such as stress, weight loss, and excessive physical exercise that are known to negatively impact gonadal axis activity.
Methods
In this overview, we described the most common forms of FHA, in particular stress-induced amenorrhea and overtraining-induced amenorrhea. In addition, although its mechanisms can differ from those involved in FHA, we reviewed the available literature on drug-induced amenorrhea, highlighting the clear connection between this condition and psychoactive drugs such as antipsychotics, antidepressants and anti-epilectics thus raising concern about the role that the abuse of substances such as opioids or alcohol can possibly have on the growing unexplained infertility of the female population.
Similar content being viewed by others
References
Gordon CM, Ackerman KE, Berga SL et al (2017) Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 102(5):1413–1439
Sowińska-Przepiera E, Andrysiak-Mamos E, Jarząbek-Bielecka G et al (2014) Functional hypothalamic amenorrhoea—diagnostic challenges, monitoring, and treatment. Endokrynol Polska 66(5):252–260
Bomba M, Gambera A, Bonini L et al (2007) Endocrine profiles and neuropsychologic correlates of functional hypothalamic amenorrhea in adolescents. Fertil Steril 87(4):876–885
Genazzani AD, Chierchia E, Santagni S et al (2010) Hypothalamic amenorrhea: from diagnosis to therapeutical approach. Ann Endocrinol 71:163–169
Prokai D, Berga S (2016) Neuroprotection via reduction in stress: altered menstrual patterns as a marker for stress and implications for long-term neurologic health in women. Int J Mol Sci 17:2147
Bomba M, Corbetta F, Bonini L et al (2014) Psychopathological traits of adolescents with functional hypothalamic amenorrhea: a comparison with anorexia nervosa. Eat Weight Disord 19(1):41–48
Pentz I, Nakić Radoš S (2017) Functional hypothalamic amenorrhea and its psychological correlates: a controlled comparison. J Reprod Infant Psychol 35(2):137–149
Rafique N, Al-Sheikh MA (2018) Prevalence of menstrual problems and their association with psychological stress in young female students studying health sciences. Saudi Med J 39:67–73
Caronia LM, Martin C, Welt CK et al (2011) A Genetic basis for functional hypothalamic amenorrhea. N Engl J Med 364(3):215–225
Schneiderman Ironson G, Siegel SD (2005) Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol 1:607–628
Meczekalski B, Katulski K, Czyzyk A et al (2014) Functional hypothalamic amenorrhea and its influence on women’s health. J Endocrinol Invest 37:1049–1056
Petraglia F, Porro C, Facchinetti F et al (1986) Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine. Life Sci 38(23):2103–2110
Rossmanith WG, Wirth U, Sterzik K, Yen SS (1989) The effects of prolonged opioidergic blockade on LH pulsatile secretion during the menstrual cycle. J Endocrinol Invest 12(4):245–252
Wahab F, Atika B, Ullah F et al (2018) Metabolic impact on the hypothalamic kisspeptin-kiss1r signaling pathway. Front Endocrinol 9:123
Iwasa T, Matsuzaki T, Yano K et al (2018) The roles of kisspeptin and gonadotropin inhibitory hormone in stress-induced reproductive disorders. Endocr J 65(2):133–140
Kirby ED, Geraghty AC, Ubuka T et al (2009) Stress increases putative gonadotropin inhibitory hormone and decreases luteinizing hormone in male rats. Proc Natl Acad Sci U S A 106(27):11324–11329
Genazzani AD, Petraglia F, Fabbri G et al (1990) Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 54(2):222–226
Cannavo S, Curtò L, Trimarchi F (2001) Exercise-related female reproductive dysfunction. J Endocrinol Invest 24:823–832
Michopoulos V, Mancini F, Loucks TL, Berga SL (2013) Neuroendocrine recovery initiated by cognitive behavioral therapy in women with functional hypothalamic amenorrhea: a randomized, controlled trial. Fertil Steril 99(7):2084–2091.e1
Berga SL, Marcus MD, Loucks TL et al (2003) Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertil Steril 80(4):976–981
Shen ZQ, Xu JJ, Lin JF (2013) Resumption of menstruation and pituitary response to gonadotropin-releasing hormone in functional hypothalamic amenorrhea subjects undertaking estrogen replacement therapy. J Endocrinol Invest 36:812–815
Böttcher B, Seeber B, Leyendecker G, Wildt L (2017) Impact of the opioid system on the reproductive axis. Fertil Steril 108(2):207–213
Roozenburg BJ, van Dessel HJ, Evers JL, Bots RS (1997) Successful induction of ovulation in normogonadotrophic clomiphene resistant anovulatory women by combined naltrexone and clomiphene citrate treatment. Hum Reprod 12:1720
Genazzani AD, Despini G, Czyzyk A et al (2017) Modulatory effects of l-carnitine plus l- acetyl-carnitine on neuroendocrine control of hypothalamic functions in functional hypothalamic amenorrhea (FHA). Gynecol Endocrinol 33(12):963–967
Mircea CN, Lujan ME, Pierson RA (2007) Metabolic fuel and clinical implications for female reproduction. J Obstet Gynaecol Can 29(11):887–902
Manfredi-Lozano M, Roa J, Tena-Sempere M (2018) Connecting metabolism and gonadal function: novel central neuropeptide pathways involved in the metabolic control of puberty and fertility. Front Neuroendocrinol 48:37–49
Ruegsegger GN, Booth FW (2017) Running from disease: molecular mechanisms associating dopamine and leptin signaling in the brain with physical inactivity, obesity, and type 2 diabetes. Front Endocrinol 8(109):1–8
Mastorakos G, Pavlatou M, Diamanti-Kandarakis E, Chrousos GP (2005) Exercise and the stress system. Hormones 4(2):73–89
De Souza MJ, Williams NI (2004) Physiological aspects and clinical sequelae of energy deficiency and hypoestrogenism in exercising women. Hum Reprod Update 10(5):433–448
Maïmoun L, Georgopoulos NA, Sultan C (2014) Endocrine disorders in adolescent and young female athletes: impact on growth, menstrual cycles, and bone mass acquisition. J Clin Endocrinol Metab 99:4037–4050
Loucks AB, Thuma JR (2003) Luteinizing hormone pulsatility is disrupted at threshold availability of energy availability in regularly menstruating women. J Clin Endocrinol Metab 88:297–311
Chan JL (2005) Mantzoros CS Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 366(9479):74–85
Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351(10):987–997
De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G, Expert Panel (2014) Female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad. Br J Sports Med 48:289
Mountjoy M, Sundgot-Borgen J, Burke L, Carter S, Constantini N, Lebrun C, Meyer N, Sherman R, Steffen K, Budgett R, Ljungqvist A (2014) The IOC consensus statement: beyond the female athlete triad-relative energy deficiency in sport (RED-S). Br J Sports Med 48(7):491–497
Beumont PJ, Gelder MG, Friesen GH, Harris GW, MacKinnon PC, Mandelbrote BM, Wiles DH (1974) The effects of phenothiazines on endocrine function: I: patients with inappropriate lactation and amenorrhoea. Br J Psychiatry 124:413–419
Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64(20):2291–2314
Cookson J, Hodgson R, Wildgust HJ (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 26(5 Suppl):42–51
Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S (2007) Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 68(3):361–367
Smith SM (2008) The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 22(2 Suppl):63–69
Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll CU, Kishimoto T (2013) The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res 147(2–3):383–386
Montejo ÁL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, Del Pino-Montes J, García-Escudero MA, García-Rizo C, González-Pinto A, Hernández AI, Martín-Carrasco M, Mayoral-Cleries F, Mayoral-van Son J, Mories MT, Pachiarotti I, Pérez J, Ros S, Vieta E (2017) Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol 45:25–34
Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J (2017) Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology 234(22):3279–3297
Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, Gunnell D (2017) Influences on antidepressant prescribing trends in the UK: 1995–2011. Soc Psychiatry Psychiatr Epidemiol 52(2):193–200
Arya DK (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 165(6):728–733
Nicholas L, Dawkins K, Golden RN (1998) Psychoneuroendocrinology of depression: prolactin. Psychiatr Clin North Am 21(2):341–358
Cam B, Karldere T (2014) Amenorrhea associated with duloxetine: two case reports. J Clin Psychopharmacol 34(4):522–523
Anand VS (1985) Clomipramine–induced galactorrhoea and amenorrhoea. Br J Psychiatry 147:87–88
International Narcotics Control Board (INCB). Narcotic drugs technical report: Estimates world requirements for 2018—statistics for 2016. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2017/Narcotic_drugs_technical_publication_2017.pdf. Accessed 29 August 2018
Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, Hao W, Johnson DT, Mohar A, Pavadia J, Samak AK, Sipp W, Sumyai V, Suryawati S, Toufiq J, Yans R, Mattick RP (2016) Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 387(10028):1644–1656
Helmerhorst GT, Teunis T, Janssen SJ, Ring D (2017) An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next? Bone Joint J 99(7):856–864
European Drug Report 2017: trends and developments; EMCDDA, Lisbon, June 2017. http://www.emcdda.europa.eu/publications/edr/trends-developments/2017. Accessed 29 August 2018
Smith HS, Elliott JA (2012) Opioid-induced androgen deficiency (OPIAD). Pain Physician 15(3 Suppl):ES145–ES156
O’Rourke TK Jr, Wosnitzer MS (2016) Opioid-induced androgen deficiency (OPIAD): diagnosis, management, and literature review. Curr Urol Rep 17(10):76
Orstead KM, Spies HG (1987) Inhibition of hypothalamic gonadotropin-releasing hormone release by endogenous opioid peptides in the female rabbit. Neuroendocrinology 46(1):14–23
Gabriel SM, Simpkins JW, Kalra SP (1983) Modulation of endogenous opioid influence on luteinizing hormone secretion by progesterone and estrogen. Endocrinology 113(5):1806–1811
Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K (2000) Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 85(6):2215–2222
Daniell HW (2008) Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 9(1):28–36
Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC (2010) The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 31(1):98–132
Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Larry Nicholson R, Bureau Y, Friedman TC, Van Uum SH (2009) Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes 117(1):38–43
GBD Alcohol Collaborators (2018) Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 10152:1015–1035
Rachdaoui N, Sarkar DK (2013) Effects of alcohol on the endocrine system. Endocrinol Metab Clin N Am 42(3):593–615
Mello NK, Mendelson JH, King NW, Bree MP, Skupny A, Ellingboe J (1988) Alcohol self-administration by female macaque monkeys: a model for study of alcohol dependence, hyperprolactinemia and amenorrhea. J Stud Alcohol 49(6):551–560
Mendelson JH, Mello NK (1988) Chronic alcohol effects on anterior pituitary and ovarian hormones in healthy women. J Pharmacol Exp Ther 245(2):407–412
Oomizu S, Boyadjieva N, Sarkar DK (2003) Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Alcohol Clin Exp Res 27(6):975–980
De A, Boyadjieva N, Oomizu S, Sarkar DK (2002) Ethanol induces hyperprolactinemia by increasing prolactin release and lactotrope growth in female rats. Alcohol Clin Exp Res 26(9):1420–1429
Lomniczi A, Mastronardi CA, Faletti AG, Seilicovich A, De Laurentiis A, McCann SM, Rettori V (2000) Inhibitory pathways and the inhibition of luteinizing hormone-releasing hormone release by alcohol. Proc Natl Acad Sci U S A. 97(5):2337–2342
Block GD, Yamamoto ME, Mallick A, Styche A (1993) Effects on pubertal hormones by ethanol abuse in adolescents. Alcohol Clin Exp Res 17:505
Dees WL, Srivastava V, Hiney JK (2009) Actions and interactions of alcohol and insulin-like growth factor-1 on female pubertal development. Alcohol Clin Exp Res 33(11):1847–1856
Li N, Fu S, Zhu F, Deng X, Shi X (2013) Alcohol intake induces diminished ovarian reserve in childbearing age women. J Obstet Gynaecol Res 39(2):516–521
Jensen TK, Hjollund NH, Henriksen TB, Scheike T, Kolstad H, Giwercman A, Ernst E, Bonde JP, Skakkebaek NE, Olsen J (1998) Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy. BMJ 317(7157):505–510
Fan D, Liu L, Xia Q, Wang W, Wu S, Tian G, Liu Y, Ni J, Wu S, Guo X, Liu Z (2017) Female alcohol consumption and fecundability: a systematic review and dose-response meta-analysis. Sci Rep 7(1):13815
Bauer J, Cooper-Mahkorn D (2008) Reproductive dysfunction in women with epilepsy: menstrual cycle abnormalities, fertility, and polycystic ovary syndrome. Int Rev Neurobiol 83:135–155
Verrotti A, D’Egidio C, Mohn A, Coppola G, Parisi P, Chiarelli F (2011) Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 52(2):199–211
Acknowledgements
The authors acknowledge Mrs. Racca Anna (annaracca@gmail.com) for her contribution to this paper.
Funding
None of the authors received funding for the realization of this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This is a review paper, therefore, no ethical approval was necessary.
Informed consent
This is a review paper, therefore, no informed consent was necessary.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lania, A., Gianotti, L., Gagliardi, I. et al. Functional hypothalamic and drug-induced amenorrhea: an overview. J Endocrinol Invest 42, 1001–1010 (2019). https://doi.org/10.1007/s40618-019-01013-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-019-01013-w